ライフサイエンスコーパス: tenecteplase

1 ients, 71 received alteplase and 75 received tenecteplase.

2 re assigned to the alteplase group and 52 to tenecteplase.

3 s selective to t-PA and its close derivative tenecteplase.

4 7.1%, p = 0.05) when compared with full-dose tenecteplase.

5 aphic flow patterns, compared with full-dose tenecteplase.

6 therapy with eptifibatide administered with tenecteplase.

7 nogen activator, reteplase, lanoteplase, and tenecteplase.

8 ents were randomly assigned (1:1) to receive tenecteplase 0.25 mg/kg (maximum 25 mg) or alteplase 0.9

9 lase (0.9 mg per kilogram of body weight) or tenecteplase (0.1 mg per kilogram or 0.25 mg per kilogra

10 The higher dose of tenecteplase (0.25 mg per kilogram) was superior to the

11 -combination regimen of 50% of standard-dose tenecteplase (0.27 microg/kg) plus high-dose eptifibatid

12 kg/min infusion) was compared with full-dose tenecteplase (0.53 microg/kg).

13 owever, in patients with target mismatch (33 tenecteplase, 35 alteplase), treatment with tenecteplase

14 B trial (tissue plasminogen activator versus tenecteplase), 49 centers carried out 2-year follow-up.

15 of recombinant tissue plasminogen activator (tenecteplase, 5 mg/kg) worsened APAP-induced liver injur

16 titutes of Health Stroke Scale score change: tenecteplase, 6; alteplase, 1; P<0.001) and better late

17 titutes of Health Stroke Scale score change: tenecteplase, 7; alteplase, 2; P=0.018) and less parench

18 Tenecteplase, a genetically engineered mutant tissue pla

19 tion (TIMI) 10, TIMI 14, and Integrillin and Tenecteplase acute MI trials.

20 reperfusion therapy in STEMI (streptokinase, tenecteplase, alteplase, and reteplase) were included.

21 imary PCI or fibrinolytic therapy with bolus tenecteplase (amended to half dose in patients >/=75 yea

22 Of 71 patients (35 assigned tenecteplase and 36 assigned alteplase) contributing to

23 ological outcomes did not differ between the tenecteplase and alteplase groups.

24 Combination therapy with reduced-dose tenecteplase and eptifibatide leads to faster, more stab

25 t detect any significant differences between tenecteplase and placebo in the primary end point of 30-

26 Tenecteplase and reteplase are comparable with accelerat

27 c stroke, 1 that demonstrated superiority of tenecteplase and the other that showed no difference bet

28 STEMI and alteplase (accelerated infusion), tenecteplase, and reteplase should be considered over st

29 d between accelerated infusion of alteplase, tenecteplase, and reteplase with parenteral anticoagulan

30 For major bleeding, a tenecteplase-based regimen tended to be associated with

31 We pooled 2 clinical trials of tenecteplase compared with alteplase for the treatment o

32 day 30, a total of 12 patients (2.4%) in the tenecteplase group and 16 patients (3.2%) in the placebo

33 eeding occurred in 32 patients (6.3%) in the tenecteplase group and 6 patients (1.2%) in the placebo

34 d day 7, a total of 6 patients (1.2%) in the tenecteplase group and 9 (1.8%) in the placebo group die

35 Stroke occurred in 12 patients (2.4%) in the tenecteplase group and was hemorrhagic in 10 patients; 1

36 occurred in 13 of 506 patients (2.6%) in the tenecteplase group as compared with 28 of 499 (5.6%) in

37 e of penumbral salvaged (68% [SD 28] for the tenecteplase group vs 68% [23] for the alteplase group;

38 nts did not differ between groups (32 in the tenecteplase group, three considered probably or definit

39 re were more intracranial hemorrhages in the tenecteplase group.

40 Together, the two tenecteplase groups had greater reperfusion (P=0.004) an

41 The newer thrombolytic drug tenecteplase has been investigated in one randomised tri

42 This sub-study of the Integrilin and Tenecteplase in Acute Myocardial Infarction (INTEGRITI)

43 Evaluation of tenecteplase in larger trials of patients with acute str

44 enemia also increased thrombus resistance to tenecteplase-induced thrombolysis in vivo.

45 Tenecteplase may offer an improved efficacy and safety p

46 improved patient outcomes when treated with tenecteplase (modified Rankin scale score 0-1: odds rati

47 ed out-of-hospital cardiac arrest to receive tenecteplase or placebo during cardiopulmonary resuscita

48 Patients were drawn from the low-dose tenecteplase plus eptifibatide arm of the INTEGRITI stud

49 nation reperfusion therapy with reduced-dose tenecteplase plus eptifibatide on continuous ST-segment

50 randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in n

51 he dose-confirmation regimen of reduced-dose tenecteplase plus high-dose eptifibatide was associated

52 ticoagulants (RR 1.47 [95% CI 1.10-1.98] for tenecteplase plus parenteral anticoagulants plus glycopr

53 failed in clinical trials and currently only tenecteplase remains to be tested as a potential alterna

54 thin 6 h of STEMI enrolled in the Enoxaparin Tenecteplase-Tissue-Type Plasminogen Activator With or W

55 e of either alteplase (tPA) (2 to 5 mg/h) or tenecteplase (TNK) (0.5 mg/h) for a total of 8 h.

56 -TIMI 23 evaluated enoxaparin with full-dose tenecteplase (TNK) and half-dose TNK plus abciximab.

57 mbinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction

58 ed by the administration of the thrombolytic Tenecteplase (TNK, 1.5 mg/kg, IV bolus) in the presence

59 We investigated whether tenecteplase-treated patients had a different 24-hour re

60 Tenecteplase-treated patients had greater early clinical

61 In the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (A

62 e aimed to assess the efficacy and safety of tenecteplase versus alteplase within 4.5 h of stroke ons

63 omized (1:1) comparison of thrombolysis with tenecteplase versus placebo in normotensive patients wit

64 morrhage (by SITS-MOST definition, 1/52 [2%] tenecteplase vs 2/51 [4%] alteplase, p=0.55; by ECASS II

65 Tenecteplase was administered to 525 patients and placeb

66 tenecteplase, 35 alteplase), treatment with tenecteplase was associated with greater early clinical

67 Tenecteplase was associated with significantly better re

68 When tenecteplase was used without adjunctive antithrombotic

69 the hypotheses that reperfusion therapy with tenecteplase would be superior to alteplase in improving